Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19798421 | 0.78 | GBA1 (0.41) | FDFT1HSD11B1 | |
| SCHEMBL1324883 | 0.77 | GBA1 (0.48) | FDFT1 | |
| SCHEMBL19798406 | 0.74 | FDFT1 (0.35) | FDFT1HSD11B1 | |
| SCHEMBL16566372 | 0.73 | FDFT1 (0.36) | FDFT1CYP2C9 | |
| SCHEMBL19798414 | 0.73 | FDFT1 (0.40) | FDFT1CYP2C9HSD11B1 | |
| SCHEMBL29226312 | 0.73 | FDFT1 (0.40) | FDFT1CYP2C9HSD11B1EPHX1 | |
| SCHEMBL19798422 | 0.71 | FDFT1 (0.39) | FDFT1 | |
| SCHEMBL19798411 | 0.71 | FDFT1 (0.39) | FDFT1CYP2C9HSD11B1 | |
| SCHEMBL16566301 | 0.71 | HSD11B1 (0.45) | FDFT1HSD11B1EPHX1 | |
| SCHEMBL18028401 | 0.70 | POLB (0.35) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | FDFT1 695/4885CYP2C9 49/4885HSD11B1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.